Prime Medicine, Inc. Common Stock (PRME)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $949.85M
Last updated: Nov 17, 2026 at 11:06 AM ET
Prime Medicine, Inc. Common Stock (PRME) Competitors
The companies most similar to Prime Medicine, Inc. Common Stock are Rigel Pharmaceuticals (RIGL), Editas Medicine (EDIT) and Intellia Therapeutics (NTLA). By market cap, Prime Medicine, Inc. Common Stock ranks 4th of the 13 companies on this page; Precigen (PGEN) is the largest at $1.63B. The median P/E of the 3 companies with a P/E is 39.3x.
Peer Comparison
PRME's revenue growth of 243.9% is above the peer median of 8.3%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Prime Medicine, Inc. Common Stock (PRME) | $949.85M | N/A | 105.5x | 0.0% | N/A | 243.9% | 0.00% |
| Rigel Pharmaceuticals Inc (RIGL) | $837.18M | 14.2x | 2.8x | 106.6% | 16.7% | 16.5% | 0.00% |
| Editas Medicine Inc (EDIT) | $334.92M | N/A | 5.6x | -145.0% | -42.3% | 37.4% | 0.00% |
| Intellia Therapeutics Inc (NTLA) | $1.36B | N/A | 26.1x | 0.0% | -50.0% | -48.0% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Precision BioSciences Inc (DTIL) | $288.76M | N/A | 4.4x | -85.6% | -38.3% | 37272.0% | 0.00% |
| Precigen Inc (PGEN) | $1.63B | 98.6x | 9.9x | 15.5% | 18.9% | 2438.0% | 0.00% |
| Pharming Group NV (PHAR) | $891.80M | 39.3x | 2.4x | 6.3% | 7.9% | 20.8% | 0.00% |
| OmniAb Inc. (OABI) | $716.17M | N/A | 15.7x | -108.1% | -17.5% | 78.3% | 0.00% |
| PepGen Ltd (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Sana Biotechnology Inc (SANA) | $605.26M | N/A | N/A | 0.0% | -46.8% | 0.0% | 0.00% |
| Design Therapeutics Inc (DSGN) | $670.46M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $693.32M | 39.3x | 5.6x | 0.0% | -28.5% | 8.3% | 0.00% |
Similar Companies
These are the 12 companies most similar to Prime Medicine, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Rigel Pharmaceuticals Inc (RIGL) | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. | RIGL competitors |
| Editas Medicine Inc (EDIT) | Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. | EDIT competitors |
| Intellia Therapeutics Inc (NTLA) | Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts. | NTLA competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Precision BioSciences Inc (DTIL) | Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. | DTIL competitors |
| Precigen Inc (PGEN) | Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland. | PGEN competitors |
| Pharming Group NV (PHAR) | Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States... | PHAR competitors |
| OmniAb Inc. (OABI) | OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. | OABI competitors |
| PepGen Ltd (PEPG) | PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious... | PEPG competitors |
| Sana Biotechnology Inc (SANA) | Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington. | SANA competitors |
| Design Therapeutics Inc (DSGN) | Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. | DSGN competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
Frequently Asked Questions About PRME
Who are Prime Medicine, Inc. Common Stock's main competitors?
The companies most similar to Prime Medicine, Inc. Common Stock include Rigel Pharmaceuticals (RIGL), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Neurogene (NGNE) and Precision BioSciences (DTIL), listed from the closest match.
Who is Prime Medicine, Inc. Common Stock's biggest competitor?
Precigen (PGEN) is the largest of the similar companies at $1.63B; Rigel Pharmaceuticals (RIGL) is the closest match by business profile, size, sector and industry.
How does PRME stock compare with its competitors?
PRME's P/S is 105.5x against a peer median of 5.6x; its net margin is 0.0% against a peer median of 0.0%.
Which of Prime Medicine, Inc. Common Stock's competitors pays a higher dividend?
Prime Medicine, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Prime Medicine, Inc. Common Stock bigger than its competitors?
No. Prime Medicine, Inc. Common Stock is 4th by market cap among the 13 companies on this page; the largest is Precigen (PGEN) at $1.63B.
PRME pages: Overview, Earnings, Forecast, Financials, Competitors